Facebook Instagram X-twitter Linkedin Youtube Spotify Apple

Duchenne News Tags: Solid Biosciences

Search
Tags
Tags
Antisense Therapeutics Astellas Pharma Avidity Biosciences BioMarin Pharmaceuticals Capricor Therapeutics Catalyst Pharmaceuticals Dyne Therapeutics Edgewise Therapeutics Entrada Therapeutics FDA FibroGen Italfarmaco ITF Therapeutics NS Pharma PepGen Percheron Therapeutics Pfizer Pliant Therapeutics Precision Biosciences PTC Therapeutics REGENXBIO Santhera Sarepta Therapeutics Satellos Bioscience Solid Biosciences Upsher-Smith Wave Life Sciences
January 14, 2026

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

On January 13, 2026, Solid Biosciences Inc. announced it will provide a corporate update outlining progress in advancing its neuromuscular and cardiac gene therapy programs in a presentation delivered by...
Read More
November 5, 2025

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

On November 3, 2025, Solid Biosciences Inc. reported financial results for the third quarter ended September 30, 2025, and announced positive new interim data from the Phase 1/2 INSPIRE DUCHENNE clinical...
Read More
August 13, 2025

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

On August 12, 2025, Solid Biosciences, Inc. reported financial results for the second quarter ended June 30, 2025, and provided a business update. They also shared a Community Letter, which...
Read More
November 7, 2024

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Business updates, third quarter financial results, and a letter to the Duchenne community.
Read More
August 14, 2024

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

On August 13, 2024, Solid Biosciences reported financial results for the second quarter ended June 30, 2024, and provided a business update. Please continue reading to view their press release. To...
Read More
November 15, 2023

Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Solid Biosciences announces clearance of an Investigational New Drug application for Duchenne gene therapy.
Read More
March 23, 2023

Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results

Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results
Read More
December 5, 2022

Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement

Solid Biosciences announces closing of its acquisition of AavantiBio
Read More
September 30, 2022

Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement

Solid Biosciences enters a definitive merger to acquire AavantiBio.
Read More
Register Now

Experience the magic this summer!

Apply Today

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Register Today

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Give Today

Accessible Vehicle Fund Applications Open

Apply Today